Arvinas, Inc.

Arvinas, Inc.

NNASDAQ:ARVN
6.82
USD
+0.05
(+0.74%)
-0.15EPS
506.64MMarket Cap
Mar 01Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.37
0.37
1.52
1.31
0.66
1.07
2.47
1.41
3.66
3.7
4.25
Basic EPS, GAAP
-0.69
-0.94
-4.4
-2.13
-3.02
-3.82
-5.31
-6.62
-2.77
-1.14
-0.15
Free Cash Flow per Basic Share
-1.1
0.2
-2.01
-1.42
-2.43
11.09
-5.27
-6.32
-3.63
-3.89
-2.47
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.05
-1.96
4.38
5.89
13.25
14.78
10.62
9.71
8.16
6.83
7.84
Tangible Book Value per Share
-1.05
-1.96
4.38
5.89
13.25
14.78
10.62
9.71
8.16
6.83
7.84
Basic Weighted Avg Shares
18
21
9
33
40
50
53
56
72
71
65
Sales/Revenue/Turnover
7
8
14
43
26
54
131
79
263
263
275
Operating Margin (%)
-246.95
-326.7
-305.8
-119.77
-466.41
-351.49
-200.3
-511.46
-94.99
-45.13
-12.13
Depreciation Expense
- -
- -
1
2
4
6
8
7
7
5
5
Net Income, GAAP
-14
-24
-41
-70
-119
-191
-282
-367
-199
-81
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-215.18
-317.32
-289.59
-163.49
-460.62
-356.34
-214.99
-467.9
-75.51
-30.77
-3.45
Working Capital
27
48
173
258
654
1,291
945
1,023
838
558
518
LT Debt
- -
- -
2
4
3
4
4
1
8
7
6
Total Equity
24
- -
137
227
642
782
565
660
562
434
514
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-38.7
-27.46
-26.83
-41.96
-59.97
-32.56
-16.23
-1.76

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
66
Market Capitalization
684
543
507

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
631
652
588
Cash, Cash Equivalents & STI
615
568
558
Accounts Receivable, Net
2
50
2
Inventories
- -
- -
- -
Total Current Liabilities
116
83
70
Payables & Accruals
58
44
29
ST Debt
2
2
2
Deferred Revenue
52
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-5.37%
-22.76%
Free Cash Flow
- -
-164.52%
5.59%
Net Income, GAAP
- -
6.56%
-59.38%
Sales/Revenue/Turnover
- -
89.42%
-0.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25
77
102
59
263
2025
189
22
42
10
263
2026
16
250
1
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.97
-0.49
-0.68
-0.63
-2.77
2025
1.14
-0.84
-0.48
-1.04
-1.14
2026
-0.9
2.61
-0.82
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Randy Teel
Full Time Employees
246
Sector
Health technology
Industry
Biotechnology
Address
5 Science Park New Haven CT United States 06511
IPO Date
Sep 27, 2018
Business
Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical company that develops protein degradation therapies using its proprietary PROTAC (PROteolysis TArgeting Chimera) platform to create small molecule drugs targeting disease-causing proteins for degradation. The company focuses on oncology and neuroscience indications, with lead product candidates including vepdegestrant (ARV-471), an oral PROTAC estrogen receptor degrader in Phase 3 clinical trials for ER+/HER2- advanced breast cancer; ARV-766, an oral PROTAC androgen receptor degrader in Phase 2 trials for prostate cancer; and ARV-102, a PROTAC targeting BCL6 for diffuse large B-cell lymphoma. Its PROTAC platform enables the design of molecules that hijack the body's ubiquitin-proteasome system to selectively degrade proteins previously considered "undruggable"; services include discovery research collaborations leveraging this technology for undisclosed targets. Arvinas operates primarily in the United States, with global clinical trial sites across North America, Europe, and Asia-Pacific; the company was founded in 2015 and maintains headquarters in New Haven, Connecticut. Recent developments include a strategic collaboration expansion with Pfizer Inc. in 2024 to advance PROTAC development for additional targets, positive Phase 3 interim data for vepdegestrant reported in mid-2025 supporting accelerated regulatory approval pathways, and a $1 billion financing round closed in early 2025 to fund late-stage trials and platform expansion into autoimmune diseases.

Company News

  • Arvinas to Present at Jefferies Global Healthcare Conference

  • What Arvinas (ARVN) Said on Its Q3 Earnings Call

  • Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting

  • Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript

  • What Arvinas (ARVN) Said on Its Q3 Earnings Call

  • Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates

  • Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation

  • Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

  • Reasons Why Investors Should Consider Betting on Arvinas Stock

  • Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease

  • Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®

  • Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

  • Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Arvinas to Participate in Upcoming Investor Conferences

  • Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN

  • Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

  • Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know